Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor

Author： Wong H.   Chen J.Z.   Chou B.   Halladay J.S.   Kenny J.R.   La H.   Marsters J.C.   Plise E.   Rudewicz P.J.   Robarge K.   Shin Y.   Wong S.   Zhang C.   Khojasteh S.C.  

Publisher： Informa Healthcare

ISSN： 1366-5928

Source： Xenobiotica, Vol.39, Iss.11, 2009-11, pp. : 850-861

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

By Smith Sherri   Hoyt Jennifer   Whitebread Nigel   Manna Joseph   Peluso Marisa   Faia Kerrie   Campbell Veronica   Tremblay Martin   Nair Somarajan   Grogan Michael   Castro Alfredo   Campbell Matthew   Ferguson Jeanne   Arsenault Brendan   Nevejans Jylle   Carter Bennett   Lee John   Dunbar Joi   McGovern Karen   Read Margaret   Adams Julian   Constan Alexander   Loewen Gordon   Sydor Jens   Palombella Vito   Soglia John  

Xenobiotica, Vol. 43, Iss. 10, 2013-10 ,pp. : 875-885

Informa Healthcare

Access to resources Recommend Favorite

Absorption, distribution, metabolism and excretion of the novel SARM GTx-024 [(S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide] in rats

By Kim Juhyun   Wang Ronghua   Veverka Karen A.   Dalton James T.  

Xenobiotica, Vol. 43, Iss. 11, 2013-11 ,pp. : 993-1009

Informa Healthcare

Access to resources Recommend Favorite

Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic––pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

By Liederer Bianca M.   Berezhkovskiy Leonid M.   Dean Brian J.   Dinkel Vikki   Peng Jing   Merchant Mark   Plise Emile G.   Wong Harvey   Liu Xingrong  

Xenobiotica, Vol. 41, Iss. 4, 2011-04 ,pp. : 327-339

Informa Healthcare

Access to resources Recommend Favorite

Absorption, metabolism and excretion of 4-chloro-2-methylphenoxyacetic acid (MCPA) in rat and dog

By Lappin G. J.   Hardwick T. D.   Stow R.   Pigott G. H.   van Ravenzwaay B.  

Xenobiotica, Vol. 32, Iss. 2, 2002-02 ,pp. : 153-163

Informa Healthcare

Access to resources Recommend Favorite

Synthesis, biological screening and molecular modeling studies of novel 3-chloro-4-substituted-1-(2-(1H-benzimidazol-2-yl)phenyl))-azetidin-2-ones

By Chhajed Santosh S.   Upasani Chandrashekhar D.  

Journal of Enzyme Inhibition and Medicinal Chemistry, Vol. 27, Iss. 4, 2012-08 ,pp. : 504-508

Informa Healthcare

Access to resources Recommend Favorite